Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461981 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Immune Responses of FluMist®
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00461981 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 101 participants.
The verdict
NCT00461981, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Interventions
- BIOLOGICAL TIV, Trivalent Inactivated Influenza Virus Vaccine
- BIOLOGICAL FluMist, Influenza Virus Vaccine Live
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461981
The ClinicalTrials.gov registry entry for NCT00461981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TIV, Trivalent Inactivated Influenza Virus Vaccine is the first listed.
NCT00461981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461981 about?
NCT00461981 is a clinical study titled "A Phase 2 Study to Evaluate Immune Responses of FluMist®". The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
What is the current status of trial NCT00461981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00461981?
The interventions under investigation include: TIV, Trivalent Inactivated Influenza Virus Vaccine (BIOLOGICAL), FluMist, Influenza Virus Vaccine Live (BIOLOGICAL).
Who is sponsoring clinical trial NCT00461981?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.